Cizzle and Bio-Techne Announce Completion of Evaluation Programme for Detection of CIZ1B Using ProteinSimple Branded Simple Western™ Platform
- The global lung cancer screening market is projected to grow at a CAGR of 8.1% from 2021 to 2028, reaching $4.85 billion
- New lung cancer screening guidelines in the US could make 14.5 million Americans eligible for annual screening, potentially saving 10,000-20,000 lives each year
- None.
The global lung cancer screening market is projected to grow from
Allan Syms, Executive Chairman of Cizzle, commented: "We are very pleased to be working with Bio-Techne, a global leader in bioscience solutions. We believe the Simple Western platform is an excellent fit for use in our development of a high throughput assay for the detection of the Company's CIZ1B biomarker. Cizzle has shown that CIZ1B is highly associated with lung cancer at its earliest stage when surgical or other therapeutic intervention is possible, which is key to saving lives. We look forward to building on this important project as we push forward in bringing our novel diagnostic solution to market."
Will Geist, President of Bio-Techne's Protein Sciences Segment Commented: "We are pleased that Cizzle has chosen the Simple Western platform for the development of its novel biomarker. The automation, sensitivity, small sample input and quantitative nature of the Simple Western system makes it ideal for supporting an assay of this nature. We are excited about the progress so far and hopeful Simple Western can aid in making such a life-saving innovation available to the patients that need it."
Enquiries:
Cizzle Biotechnology Holdings plc | Via IFC Advisory |
Allan Syms (Executive Chairman) | |
Allenby Capital Limited | +44(0) 20 3328 5656 |
John Depasquale | |
George Payne | |
Novum Securities Limited | +44(0) 20 7399 9400 |
Colin Rowbury Jon Bellis | |
IFC Advisory Limited | +44(0) 20 3934 6630 |
Tim Metcalfe | |
Bio-Techne Corporation David Clair | +1 612-656-4416 |
About Cizzle Biotechnology
Cizzle is developing a blood test for the early detection of lung cancer. The Company is a spin- out from the University of
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnosis. With thousands of products in its portfolio, Bio-Techne generated approximately
*Lung Cancer Screening Market Size & Share | Report, 2028 (fortunebusinessinsights.com)
** The 2021 USPSTF lung cancer screening guidelines: a new frontier - The Lancet Respiratory Medicine
View original content to download multimedia:https://www.prnewswire.com/news-releases/cizzle-and-bio-techne-announce-completion-of-evaluation-programme-for-detection-of-ciz1b-using-proteinsimple-branded-simple-western-platform-301931312.html
SOURCE Bio-Techne Corporation